Profile data is unavailable for this security.
About the company
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.
- Revenue in CAD (TTM)4.08m
- Net income in CAD-17.07m
- Incorporated1997
- Employees40.00
- LocationStageZero Life Sciences Ltd30-70 East Beaver Creek RoadRICHMOND HILL L4B 3B2CanadaCAN
- Phone+1 (905) 209-2030
- Fax+1 (905) 209-2030
- Websitehttps://www.stagezerolifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appili Therapeutics Inc | 1.15m | -5.34m | 4.25m | 8.00 | -- | -- | -- | 3.70 | -0.044 | -0.044 | 0.0095 | -0.0811 | 0.5047 | -- | 2.12 | -- | -234.31 | -117.41 | -- | -173.66 | -- | -- | -464.23 | -3,037.15 | -- | -5.32 | -- | -- | -75.97 | -- | 63.20 | -- | -43.04 | -- |
| Entourage Health Corp | 40.71m | -46.17m | 4.61m | 251.00 | -- | -- | -- | 0.1132 | -0.150 | -0.150 | 0.1324 | -0.4776 | 1.05 | 2.84 | 12.12 | -- | -118.59 | -55.14 | -- | -150.92 | 13.37 | -40.59 | -113.40 | -199.99 | 0.0893 | -0.8073 | 11.31 | -- | -0.438 | 38.62 | 62.51 | -- | -49.49 | -- |
| Innovotech Inc | 1.18m | -157.59k | 4.69m | 16.00 | -- | 5.03 | -- | 3.96 | -0.004 | -0.004 | 0.0304 | 0.0239 | 0.9696 | 6.62 | 5.51 | -- | -12.92 | 2.90 | -15.52 | 3.56 | 68.63 | 71.56 | -13.33 | 2.19 | 2.82 | -- | 0.00 | -- | 5.05 | 7.42 | -15.43 | -- | 35.69 | -- |
| StageZero Life Sciences Ltd | 4.08m | -17.07m | 4.92m | 40.00 | -- | -- | -- | 1.21 | -0.1609 | -0.1609 | 0.0377 | -0.10 | 0.6717 | 22.87 | 48.05 | 101,923.90 | -281.22 | -135.76 | -- | -- | 0.3457 | -2.74 | -418.64 | -246.92 | 0.0329 | -14.74 | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Principal Technologies Inc | 581.16k | -1.52m | 4.94m | -- | -- | 6.07 | -- | 8.49 | -0.0657 | -0.0657 | 0.0257 | 0.0247 | 0.577 | -- | 3.71 | -- | -147.50 | -- | -286.94 | -- | 42.98 | -- | -255.65 | -- | -- | -59.80 | 0.0757 | -- | 25.43 | -- | 23.53 | -- | -- | -- |
